Bumetanide reduces seizure frequency in patients with temporal lobe epilepsy |
| |
| Authors: | Sanaz Eftekhari Jafar Mehvari Habibabadi Massoumeh Najafi Ziarani Seyed Sohrab Hashemi Fesharaki Marzieh Gharakhani Hossein Mostafavi Mohammad Taghi Joghataei Nahid Beladimoghadam Elham Rahimian Mahmoud Reza Hadjighassem |
| |
| Affiliation: | 1. Cellular and Molecular Research Center, Tehran University of Medical Sciences, Tehran, Iran;2. Department of Neuroscience, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran;3. Shefa Neuroscience Research Center, Tehran, Iran;4. Isfahan Neuroscience Research Center, Isfahan University of Medical Sciences, Isfahan, Iran;5. Stem Cell Technology Research Center, Molecular Biology and Genetic Engineering Department, Tehran, Iran;6. Zanjan University of Medical Sciences, Zanjan, Iran;7. Shahid Beheshti University of Medical Sciences, Tehran, Iran |
| |
| Abstract: | Alterations in the balance of K‐Na‐2Cl cotransporter (NKCC1) and Na‐Cl cotransporter (KCC2) activity may cause depolarizing effect of γ‐aminobutyric Acid (GABA), and contribute to epileptogenesis in human temporal lobe epilepsy. NKCC1 facilitates accumulation of chloride inside neurons and favors depolarizing responses to GABA. In the current pilot study we provide the first documented look at efficacy of bumetanide, a specific NKCC1 antagonist, on reduction of seizure frequency in adult patients with temporal lobe epilepsy. According to our results, seizure frequency was reduced considerably in these patients. Furthermore, epileptiform discharges decreased in two of our patients. If the efficacy of bumetanide is proven in large scale studies, it can be used as a supplemental therapy in temporal lobe epilepsy. |
| |
| Keywords: | Bumetanide Temporal lobe epilepsy NKCC1 GABA |
|
|
